Ahaviah Glaser has joined the Generic Pharmaceutical Association (GPhA) as vice president for Policy & Strategic Alliances, effective immediately. Glaser joins the Association from AARP’s Government Affairs team and the Law & Government Program of American University’s Washington College of Law.
“Through GPhA and the newly-created Affordable Medicines Research Institute, Havi will help educate both the public at large and policy makers around the world about the safety and efficacy of generic medicines as well as the extraordinary health care savings that generics provide,” said GPhA President and CEO Ralph G. Neas, in a statement
“In a time when budget challenges and health care costs are colliding as never before, not only for governments but for families, Havi’s job will be to help shepherd research, education and outreach efforts to ensure that all Americans fully understand that generic pharmaceuticals reduce health care costs while maintaining the high-quality standard of care that they rightly expect,” Neas added.
Glaser’s hiring represents a significant step in GPhA’s plan to use cutting-edge research and strategic alliances to make sure that the importance of generic medicines is widely understood, especially in emerging opportunities such as the generic biologics market.
Ms. Glaser has a wide-ranging background, which will help ensure that GPhA’s policy concerns will be approached from multiple angles. She holds a law degree from the University of Michigan and earned a Bachelor of Science degree from the University of California at Berkeley. As an attorney, she has litigated key cases in the private sector, lobbied Congress, drafted legislation, worked with regulatory agencies and led diverse coalitions, all in an effort to expand access to safe, affordable prescription medication.
She is also an experienced educator, most recently serving as an adjunct professor in the Washington College of Law’s Health Law and Policy Institute since 2006. Immediately before coming to GPhA, Ms. Glaser served as AARP’s lead lobbyist on Medicare, Medicaid and pharmaceutical policy.